Selecta lays off 25% of employees after strategic review

Selecta Biosciences, which is developing immunotherapies and gene therapies, is cutting its workforce by 25% and pausing development of its wholly-owned gene therapy programs.

The company announced the workforce reduction and a clinical trial pause on Thursday during its first-quarter earnings report, saying the actions would extend the biotech’s cash…